[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606193":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":21,"centralContacts":24,"locations":21,"responsibleParty":30,"collaborators":32,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":21,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":21,"enrollmentInfo":68,"targetDuration":21,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":83,"whyStopped":21,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":21},{"fullName":5,"class":6},"Tianjin Medical University Second Hospital","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"antegrade flexible ureteroscopy-assisted PCNL","EXPERIMENTAL",[12],"Procedure: antegrade flexible ureteroscopy-assisted PCNL",{"label":14,"type":6,"description":14,"interventionNames":15},"single PCNL",[16],"Procedure: single PCNL",[18,22],{"type":19,"name":9,"description":9,"armGroupLabels":20,"otherNames":21},"PROCEDURE",[9],null,{"type":19,"name":14,"description":14,"armGroupLabels":23,"otherNames":21},[14],[25],{"name":26,"role":27,"phone":28,"phoneExt":21,"email":29},"Yuanjiong Qi","CONTACT","022-88328695","qiyuanjiong@163.com",{"type":31,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[33,35,37,39,41,43,45,47,49,51,53,55,57],{"name":34,"class":6},"Chinese PLA General Hospital",{"name":36,"class":6},"Tianjin Medical University General Hospital",{"name":38,"class":6},"Peking University People's Hospital",{"name":40,"class":6},"First Hospital of China Medical University",{"name":42,"class":6},"The Second Affiliated Hospital of Dalian Medical University",{"name":44,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":46,"class":6},"Second Affiliated Hospital of Guangzhou Medical University",{"name":48,"class":6},"The First Affiliated Hospital with Nanjing Medical University",{"name":50,"class":6},"Beijing Tsinghua Changgeng Hospital",{"name":52,"class":6},"The First Affiliated Hospital of Soochow University",{"name":54,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"name":56,"class":6},"The Affiliated Hospital of Qingdao University",{"name":58,"class":6},"Wuhan TongJi Hospital","100606193","safety-and-effectiveness-of-antegrade-flexible-ureteroscopy-assisted-percutaneous-nephrolithotomy-for-staghorn-calculi-100606193",false,"NCT07172373","Safety and Effectiveness of Antegrade Flexible Ureteroscopy-Assisted Percutaneous Nephrolithotomy for Staghorn Calculi","Safety and Efficacy of Antegrade Flexible Ureteroscopy-Assisted Percutaneous Nephrolithotomy for Staghorn Calculi: A Prospective Multicenter Clinical Study","Inclusion Criteria:\n\nStaghorn calculi confirmed by non-contrast CT of the urinary system; Age ≥18 years; General condition suitable for surgical treatment; Ability to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\nSolitary kidney or congenital anomalies (such as horseshoe kidney or ectopic kidney); Patients with severe preoperative pyelonephritis; Patients with psychiatric disorders or unwilling to cooperate; Patients with uncontrolled diabetes or hypertension who cannot tolerate surgery; Patients with coagulation disorders; Patients deemed unsuitable for participation in this trial by the investigator.","ALL","18 Years",{"count":69,"type":70},420,"ESTIMATED","INTERVENTIONAL",[73],"NA","Objective This study aims to evaluate the safety and efficacy of antegrade flexible ureteroscopy-assisted PCNL for the treatment of staghorn calculi, compared with standard PCNL.\n\nMethods This prospective, multicenter, randomized controlled trial plans to enroll 420 patients with staghorn calculi, randomly assigned into two groups: the experimental group (antegrade flexible ureteroscopy-assisted PCNL, n=210) and the control group (standard PCNL, n=210). The primary endpoint is stone-free rate (defined as no residual fragment ≥2 mm on postoperative CT). Secondary endpoints include operative time, number of percutaneous tracts, rate of secondary procedures, hemoglobin decrease, postoperative complications (Clavien-Dindo classification), and length of hospital stay. All patients will undergo CT evaluation on postoperative day 2. Subgroup analysis will be performed according to the number of stone branches (≥5 vs \\\u003C5).",[76,77],"Urolithiasis","Renal Stones",[79,80,81,82],"Percutaneous nephrolithotomy","Antegrade flexible ureteroscopy","Staghorn calculi","Stone branch number","NOT_YET_RECRUITING","2025-09-12",{"date":86,"type":87},"2025-09-15","ACTUAL",{"date":89,"type":70},"2025-10-01",{"date":91,"type":70},"2026-04-30",{"name":5,"class":6}]